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Abstract
Many genetic liver diseases present in newborns with repeated, often lethal, metabolic crises. Gene 
therapy using non-integrating viruses such as AAV is not optimal in this setting because the non-
integrating genome is lost as developing hepatocytes proliferate1,2. We reasoned that newborn liver 
may be an ideal setting for AAV-mediated gene correction using CRISPR/Cas9. Here we 
intravenously infuse two AAVs, one expressing Cas9 and the other expressing a guide RNA and 
the donor DNA, into newborn mice with a partial deficiency in the urea cycle disorder enzyme, 
ornithine transcarbamylase (OTC). This resulted in reversion of the mutation in 10% (6.7% – 
20.1%) of hepatocytes and increased survival in mice challenged with a high-protein diet, which 
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exacerbates disease. Gene correction in adult OTC-deficient mice was lower and accompanied by 
larger deletions that ablated residual expression from the endogenous OTC gene, leading to 
diminished protein tolerance and lethal hyperammonemia on a chow diet.
An X-linked deficiency of the OTC enzyme in humans causes recurrent and life-threatening 
episodes of hyperammonemia3,4. In males hemizygous for OTC deficiency, the first 
metabolic crisis usually occurs in the newborn period and is associated with up to 50% 
mortality, with survivors typically undergoing liver transplantation in the first year of life5. 
An animal model of OTC deficiency, the male sparse fur ash (spfash) mouse, has a G-to-A 
point mutation at the donor splice site at the end of exon 4 of the OTC gene, which leads to 
abnormal splicing and a 20-fold reduction in OTC mRNA and protein6. Affected animals 
have 5% residual OTC activity and can survive on a chow diet, but they develop 
hyperammonia that can be lethal when provided a high-protein diet.
In vivo genome editing of disease-causing mutations is a promising approach for the 
treatment of genetic disorders7–17. We developed a strategy using a dual-AAV system based 
on AAV8, which has high liver tropism to correct the point mutation in newborn spfash mice 
using Cas9 enzyme from Staphylococcus aureus (SaCas9)11–13. Prior to incorporating the 
individual components of the system into AAV8 vectors, we searched for protospacer-
adjacent motif (PAM) sequences (NNGRRT) in proximity to the spfash mutation of the OTC 
gene and identified potential 20-nt protospacer sequences. Three sequences, sgRNA1–3 
(Fig. 1a), were further evaluated following transfection of puromycin-containing plasmids 
into a mouse MC57G cell line. Evidence for double-strand breaks (DSBs) and the formation 
of indels at the desired site was demonstrated using the SURVEYOR assay (Supplementary 
Fig. 1a). One protospacer located within the adjacent intron (i.e., sgRNA3) failed to yield 
indels in this in vitro assay, while the others generated indels at the desired sites 
(Supplementary Fig. 1a). We selected the protospacer with a PAM within the adjacent intron 
(sgRNA1) because non-homologous end joining (NHEJ) without homology directed repair 
(HDR) within an exon could ablate residual OTC activity of the hypomorphic spfash 
mutation, thereby reducing residual ureagenesis. A plasmid cassette co-expressing the 
sgRNA1 guide RNA and SaCas9 was co-transfected with a plasmid containing a donor DNA 
template with approximately 0.9 kb of sequence flanking each side of the mutation. We 
mutated the corresponding PAM sequence in the donor template to reduce re-cleavage after 
HDR and included an AgeI site facilitate detection of HDR, which was achieved with high-
efficiency (Supplementary Fig. 1b).
A two-vector approach was necessary to incorporate all components into AAV (Fig. 1b). 
Vector 1 expressed the SaCas9 gene from a liver-specific TBG promoter (subsequently 
referred to as AAV8.SaCas9), while vector 2 contained the sgRNA1 sequence expressed 
from the U6 promoter and the 1.8 kb donor OTC DNA sequence (referred to as 
AAV8.sgRNA1.donor). In all experiments, spfash pups were injected intravenously on 
postnatal day 2 with mixtures of vector 1 and vector 2 and subsequently evaluated for indel 
formation and functional correction of the spfash mutation (Fig. 1c).
We obtained liver samples from treated spfash animals, untreated spfash (spfash controls), 
wildtype littermates, and spfash mice administered AAV8.SaCas9 with a modified 
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AAV8.control.donor without guide RNA (untargeted) at 1, 3, and 8 weeks following vector 
infusion. Pilot experiments elucidated optimal conditions of vector infusion with respect to 
doses and ratios of the two vectors (Supplementary Fig. 2). We administered 5×1011 genome 
copies (GC) of AAV8.sgRNA1.donor (or AAV8.control.donor) and 5×1010 GC of 
AAV8.SaCas9 in all newborn mouse experiments.
We analyzed the targeted region of the OTC gene by deep sequencing of PCR amplicons of 
liver tissue harvested 3 weeks (n=3) and 8 weeks (n=3) after vector treatment, and one 
untreated spfash mouse (Supplementary Table 1). More detailed descriptions of the actual 
indels from a subset of these animals is summarized in Supplementary Table 2. Following 
gene correction, indels were detected in 31% (26.5% – 35.5%) of OTC alleles from the 6 
treated animals (Supplementary Table 1). More detailed studies in two treated mice 
indicated that over 90% of the deletions were less than 20 bp and only 1% extended into the 
adjacent exon (Supplementary Table 3). HDR-based correction of the G-to-A mutation was 
observed in 10% (6.7% – 20.1%) of OTC alleles from 6 treated animals (Supplementary 
Table 1). Analysis of amplified DNA between the G-to-A mutation and the donor-specific, 
altered PAM located 51 nt into the adjacent intron showed that approximately 83% of 
corrected alleles contained only donor derived-sequences between these two landmarks 
(reads with perfect HDR, Supplementary Table 1), while 3.5% of total OTC alleles had 
evidence of incomplete HDR events (reads with partial HDR, Supplementary Table 1). 
HDR-mediated targeted modifications were also estimated by the presence of a restriction-
fragment length polymorphism (RFLP) introduced into the donor DNA in three animals 
harvested at each of the three time points. The average rate of HDR was 2.6% at 1 week, 
18.5% at 3 weeks, and 14.3% at 8 weeks, confirming the high rate of HDR observed by deep 
sequencing (Supplementary Fig. 3a).
The algorithm described in www.benchling.com identified 49 potential off-target sites for 
sgRNA1. The top 16 sites most likely to create DSBs were amplified by PCR and deep 
sequenced (Supplementary Table 4). Samples from treated animals did not show indel rates 
above background (indel rates in untreated animals due to sequencing error, usually a 
fraction of a percent).
Tissue sections of liver were analyzed by immunohistochemistry for OTC expression. No 
signal (<1%) was observed in the spfash controls, while analysis of heterozygotes showed the 
predicted mosaicism (Fig. 2a). Morphometry indicated over 100-fold higher numbers of 
OTC-expressing cells in treated groups than found in the spfash control groups (Fig. 2b; 15% 
(6.8% – 24.4%) at 3 weeks and 13% (7.5% – 20.1%) at 8 weeks). Treated animals showed 
patches of OTC-expressing cells (Fig. 2c) that localized within all portions of the portal axis 
except around central veins, as predicted for endogenous OTC18 Higher magnification 
showed clusters of OTC-expressing hepatocytes consistent with correction followed by 
clonal expansion in the context of the growing liver (Fig. 2d). Direct measurements of OTC 
enzyme activity from liver homogenates and OTC mRNA from total cellular liver RNA 
revealed similarly high levels of correction in treated animals, resulting in 20% (13.4% – 
33.7%) and 16% (11.0% – 25.4%) of normal OTC enzyme activity at 3 and 8 weeks, 
respectively (Fig. 2e), and 13% (8.6% – 21.8%) and 9% (5.0% – 16.8%) of normal OTC 
mRNA at 3 and 8 weeks, respectively (Fig. 2f). Despite the decrease in OTC+ hepatocytes, 
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OTC enzyme activity, and OTC mRNA expression from 3 to 8 weeks, none of these 
differences were statistically significant (Fig. 2b; p=0.4828, Fig. 2e; p=0.2723, Fig. 2f; 
p=0.1475, respectively). OTC protein levels in liver of most treated animals were higher than 
in spfash controls but did not reach the levels found in wild-type mice (Supplementary Fig. 
3b). Overall, there was good correlation of the estimates of correction based on histology, 
protein, and mRNA within individual animals.
One concern about using AAV to deliver SaCas9 is the virus’s propensity to achieve stable 
transgene expression, which is not necessary to accomplish editing and may in fact 
contribute to immune and/or genome toxicity. Western blot analysis showed high level 
SaCas9 protein at 1 week that declined to undetectable levels by 8 weeks (Supplementary 
Fig. 3b). Furthermore, immunohistochemistry revealed nuclear-localized SaCas9 protein in 
21% of hepatocytes at one week, which declined to undetectable levels (<0.1% hepatocytes) 
by 8 weeks (Fig. 3a). SaCas9 mRNA declined 43-fold during this 7-week period, to very low 
but still detectable levels (Fig. 3b). A 25-fold reduction in SaCas9 DNA during this same 
time interval indicates that elimination of vector genomes in the setting of the proliferating 
newborn liver is a primary contributor to the desired decline of SaCas9 expression (Fig. 3c). 
SaCas9 mRNA/vector copy did not change over time, indicating that the TBG promoter was 
still active.
In assessing the impact of gene correction on the clinical manifestations of OTC deficiency, 
we evaluated the tolerance of spfash mice to a one-week course of a high-protein diet and 
found that blood ammonia was elevated from 83 ± 9 μM (n=13) in wild type controls to 312 
± 30 μM (n=16) in the spfash controls at the end of the diet course (Fig. 3d; p<0.0001). 
Substantial variation in blood ammonia levels was found in untreated spfash animals after the 
one-week diet course, which is consistent with findings in OTC-deficient patients, who show 
large fluctuations in ammonia over relatively short periods of time3. There was no 
significant difference between untreated spfash and untargeted spfash controls (Fig. 3d; 
p=0.83). In contrast, we observed a statistically significant 40% reduction in ammonia in 
treated as compared to untreated spfash animals (Fig. 3d; p=0.0014), and treated spfash mice 
showed a survival improvement (Fig. 3e; p=0.03). During the course of the high-protein diet, 
30% of both untreated spfash (n=20) and untargeted spfash animals (n=13) developed clinical 
signs of hyperammonemia and died or had to be euthanized, while all of the wild type mice 
(n=13) and treated spfash mice (n=13) survived (Fig. 3e). Detailed histological analyses of 
liver and transaminase levels (both alanine and aspartate aminotransferase, ALT and AST, 
respectively) in SaCas9-treated spfash mice harvested at the end of the high-protein diet 
challenge failed to reveal any pathology or toxicity (Supplementary Fig. 4).
Based on encouraging results in newborn spfash mice, we then conducted similar studies in 
adult spfash mice, which were infused with two different doses of the AAV vectors and 
euthanized 2 to 3 weeks later. Sequence analysis of on-target DNA amplicons revealed 
remarkably high frequencies of indels at both low and high vector doses (Table 1; 44.6% 
(38.5% – 50.3%) and 42.0% (34.0% – 48.5%), respectively) but low levels of gene 
correction as measured by reversion of the G-to-A mutation (Table 1; 0.3% (0.2% – 0.3%) 
and 1.7% (1.3% – 2.1%), respectively). Additional evidence of correction was provided by 
immunofluorescence analysis of liver for OTC expression that showed 2.2% (0.71%, 2.51%, 
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3.45%) and 6.0% (3.11%, 5.05%, 9.86%) positive cells in low- and high-dose animals, 
respectively (Fig. 4a; n=3 per group). Adults showed a pattern of isolated OTC-positive cells 
(Fig. 4b), while clusters of OTC-positive cells were present in newborns (Fig. 3c). Between 
3 to 4 weeks after treatment with low-dose vectors, the animals unexpectedly became sick 
and by week 5 all had to be euthanized (Fig. 4c). This toxicity was more severe in the high-
dose animals, requiring termination of the study at 2 weeks (Fig. 4d). Further analysis of 
symptomatic animals demonstrated dose-dependent elevations of urine orotate (Fig. 4e) and 
plasma ammonia (Fig. 4f) on a chow diet. These findings suggested a compromise of 
residual ureagenesis that could not be explained by liver damage since liver histology 
appeared normal (Supplementary Fig. 5a) and serum transaminases were slightly, but not 
statistically, elevated over control groups (Supplementary Fig. 5b). Deep sequencing of the 
targeted region of the OTC gene revealed a surprising number of large deletions in adults as 
compared to what was observed in newborns, with 6.5% extending into the adjacent exon in 
adults as opposed to 1% in newborns (Supplementary Table 3). The more complex and 
extensive indels in adult spfash mice were unlikely to have been caused by higher and/or 
more persistent Cas9 expression since Cas9 mRNA was lower in 3-week adults (Fig. 4g) 
than in any liver tissues harvested up to 8 weeks after injection in newborns (Supplementary 
Fig. 6a and b). We speculate that different NHEJ mechanisms may exist in non-dividing 
adult hepatocytes versus dividing newborn hepatocytes that affects the quality of the DNA 
repair response.
A key challenge in using the CRISPR/Cas9 system to correct a mutation in vivo is delivering 
the three components of the system (sgRNA, Cas9, and donor DNA) into the same cell in a 
way that is safe and efficient19,20. One recent report in the literature approached a similar 
challenge by utilizing chemically modified mRNA to deliver therapeutic levels of another 
site-specific endonuclease into murine lung21. Here, we leveraged our experience with liver-
directed gene replacement therapy with highly hepatotropic AAV vectors22 to move closer to 
realizing these goals in a model of liver metabolic disease. While the focus on newborn 
animals was driven by a compelling unmet need in patients with these lethal metabolic 
diseases, it also created some unique technical advantages. The surprisingly high level of 
correction in our newborn experiments is likely due to high expression of SaCas9 with 
abundant donor DNA in the context of dividing cells. Our previous studies of AAV8 gene 
transfer in newborn monkeys demonstrated the same high peak levels of transduction and 
gene transfer (i.e., 92% hepatocytes expressing GFP and 32 vector genomes per cell) as 
achieved in mice administered the same dose of GFP-expressing vector (i.e., 80% 
hepatocytes expressing GFP and 14 vector genomes per cell) with similar kinetics of 
decline, which is encouraging in terms of translation to larger species including humans2,23.
Issues of safety relate primarily to the expression of Cas9 in the context of an sgRNA that 
could create off-target DSBs with carcinogenic sequelae, although our findings in the adult 
mice suggest that large on-target deletions could potentially be a safety issue in some 
contexts. More extensive characterization of these potential toxicities is necessary before 
clinical translation can be considered24,25, although, in animals treated as newborns, we 
could not detect indels of likely off-target sites at the level of sensitivity achieved by deep 
sequencing. Cas9 could also elicit pathologic immune responses16, as has been observed in 
gene replacement therapies in which the transgene is a foreign protein. However, systemic 
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delivery of AAV in a newborn helps mitigate potential immunologic adverse events for 
several reasons26–28. First, expression of the prokaryotic SaCas9 protein is transient because 
the non-integrated vector is lost during hepatocyte proliferation1. Furthermore, we have 
shown that exposure of newborn rhesus macaques to AAV-encoded proteins induces 
tolerance to these proteins, thereby circumventing toxicity caused by destructive adaptive 
immune responses29.
This study provides convincing evidence for efficacy in an authentic animal model of a 
lethal human metabolic disease following in vivo genome editing. Furthermore, our 
observation of dramatic differences in clinical outcome following HDR-mediated gene 
correction of newborn versus adult animals illustrates potential unintended consequences of 
NHEJ-mediated ablation of residual function in hypomorphic mutant genes that may 
complicate some applications of therapeutic genome editing.
Online Methods
Plasmid construction
The smaller-sized Cas9 from Staphylococcus aureus (SaCas9) is more suitable for 
packaging into an AAV vector. We codon-optimized FLAG-tagged SaCas9 according to 
human codon usage (hSaCas9) and constructed pX330.hSaCas9 by replacing the hSpCas9 
and sgRNA scaffold in pX330 with hSaCas9 and SaCas9 sgRNA scaffold. Three 20-nt target 
sequences preceding a 5′NNGRRT PAM sequence were selected for OTC gene editing. A 
puromycin-resistance gene cassette was cloned into pX330.hSaCas9-derived plasmids for 
selection of transfected cells following in vitro transient transfection. To generate a dual 
AAV vector system for in vivo OTC gene correction by SaCas9, we constructed two AAV 
cis-plasmids: 1) the hSaCas9 was subcloned from pX330.hSaCas9 into an AAV backbone 
plasmid containing the full-length TBG promoter (two copies of enhancer elements of the α 
microglobulin/bikunin gene followed by a liver-specific TBG promoter) and the bovine 
growth hormone polyadenylation sequence, yielding AAV8.SaCas9; 2) the 1.8-kb OTC 
donor template was cloned into the pAAV backbone, and the U6-OTC sgRNA1 cassette was 
inserted into the AflII site, yielding AAV8.sgRNA1.donor. The PAM sequence in the donor 
template in AAV8.sgRNA1.donor was mutated to prevent re-cleavage by Cas9 after HDR, 
and an AgeI site was added to facilitate detection of HDR (Supplementary Table 5). The 
“untargeted” AAV8.control.donor differs from the “targeted” AAV8.sgRNA1.donor by 
eliminating the protospacer from the U6-OTC sgRNA1 cassette. All plasmid constructs were 
verified by sequencing.
AAV vector production
All AAV8 vectors were produced by the Penn Vector Core at the University of Pennsylvania 
as previously described30. The genome titer (GC mL−1) of AAV vectors was determined by 
quantitative PCR (qPCR). All vectors used in this study passed the endotoxin assay using the 
QCL-1000 Chromogenic LAL test kit (Cambrex Bio Science).
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Cell culture and transfection
MC57G cells (ATCC) were maintained in DMEM medium supplemented with 10% FBS 
and cultured at 37°C with 5% CO2. Cell lines were used directly upon receipt from ATCC 
and were not authenticated or tested for mycoplasma contamination. For in vitro target 
and/or donor template testing, plasmids were transfected into MC57G cells using 
Lipofectamine® LTX with Plus™ reagent (Life Technology) per manufacturer’s 
recommendations. Transfected cells were under puromycin (4 μg mL−1) selection for 4 days 
to enrich transfected cells.
Genomic DNA extraction and SURVEYOR assay
Genomic DNA from transfected MC57G cells was extracted using the QuickExtract DNA 
extraction solution (Epicentre Biotechnologies). The efficiency of each individual sgRNA 
was tested by the SURVEYOR nuclease assay (Transgenomics) as described previously31 
using the PCR primers listed in Supplementary Table 5.
Animal studies
spfash mice were maintained in an AAALAC (Association for Assessment and Accreditation 
of Laboratory Animal Care)-accredited and PHS (Public Health Service)-assured facility at 
the University of Pennsylvania, as described previously32. All animal procedures were 
performed in accordance with protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Pennsylvania. Mating cages were monitored daily 
for births. Newborn (postnatal day 2, p2) male pups received a temporal vein injection of the 
mixture of two vectors at the intended doses for each in a volume of 50 μl, as described33. 
Untreated wild-type (WT), spfash heterozygous (Het), and spfash hemizygous mice served as 
controls. Mice were sacrificed at 1, 3, or 8 weeks after vector treatment, and liver samples 
were harvested for analyses. Mice were genotyped at weaning or at the time of necropsy to 
confirm genotype.
For testing the efficacy of OTC correction, a high-protein diet (40% protein, Animal 
Specialties & Provisions) was given to 7-week-old mice for 7 days. After this time, plasma 
was collected for measurement of plasma NH3 using the Sigma Ammonia Assay Kit. The 
remaining samples were sent to Antech Diagnostics for measurements of ALT, AST, and 
total bilirubin.
Note that the entire litter of newborn male pups was injected with either the test or control 
vectors, and no specific randomization method was used. The following assays were 
performed in a blinded fashion in which the investigator was unaware of the nature of the 
vectors or vector dose: vector injection, OTC and Cas9 (FLAG) immunostaining and 
quantification, histopathology analysis on liver, OTC enzyme activity assay, and gene 
expression analysis and RT-qPCR.
The adult gene editing experiments were conducted in 8- to 10-week-old male spfash mice. 
Animals in low-dose groups received a tail vein injection of AAV8.SaCas9 (1×1011GC) and 
AAV8.sgRNA1.donor (1×1012 GC) or untargeted vectors at the same doses, and they were 
sacrificed at 3 weeks after injection for analyses. Animals in high-dose groups received a tail 
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vein injection of AAV8.SaCas9 (1×1012 GC) and AAV8.sgRNA1.donor (5×1012 GC) or 
untargeted vectors at the same doses, and they were sacrificed at 2 weeks after injection for 
analyses.
OTC and Cas9 immunostaining
Immunofluorescence for OTC expression was performed on frozen liver sections. 
Cryosections (8 μm) were air dried and fixed in 4% paraformaldehyde (all solutions in 
phosphate-buffered saline) for 10 min. Sections were then permeabilized and blocked in 
0.2% Triton containing 1% donkey serum for 30 min. A rabbit anti-OTC antibody34 (diluted 
1:1000 in 1% donkey serum) was used to incubate the sections for 1 hr. After washing, the 
sections were stained with tetramethylrhodamine (TRITC)–conjugated donkey anti-rabbit 
antibodies (Jackson Immunoresearch Laboratories, Cat# 711–025–152) in 1% donkey serum 
for 30 min, washed, and mounted with Vectashield (Vector Laboratories).
Some sections were additionally stained with a monoclonal antibody against glutamine 
synthetase (BD Biosciences, clone 6, Cat# 610517) as a marker for pericentral hepatocytes 
followed by fluorescein isothiocyanate (FITC)-labeled donkey anti-mouse antibodies 
(Jackson Immunoresearch Laboratories, Cat# 715–095–150). Double staining was 
performed by mixing the two primary and secondary antibodies, respectively, and following 
the above protocol. Other sections were counterstained with fluorescein-labeled tomato 
lectin (Lycopersicon esculentum lectin, LEL; Vector Laboratories, Cat# FL-1171) by adding 
LEL to the secondary antibody solution at a dilution of 1:500.
Cas9 expression was detected on sections from paraffin-embedded livers via 
immunostaining for FLAG tag using monoclonal antibody M2 (Sigma, Cat# F1804). 
Paraffin sections were processed according to standard protocols with an antigen retrieval 
step (boiling for 6 min in 10 mM citrate buffer, pH 6.0). Staining was performed using a 
mouse-on-mouse (MOM) kit (Vector Laboratories) according to the manufacturer’s 
instructions.
To quantify percentages of OTC-expressing hepatocytes, 10 random images were taken with 
a 10x objective from each liver section stained for OTC expression. In some cases, where 
only a small liver section was available, only 5 pictures were taken. Using ImageJ software 
(Rasband W. S., National Institutes of Health, USA; http://rsb.info.nih.gov/ij/), images were 
thresholded for OTC-positive area (i.e. the OTC-positive area was selected) and the 
percentage of the OTC-positive area was determined for each image. In a second 
measurement the images were thresholded for “empty” area (e.g., veins and sinusoids) to 
determine the percentage of the area not occupied by liver tissue. This was possible as a 
result of the presence of weak background fluorescence of the liver tissue. The final 
percentage of OTC-positive liver tissue (i.e., OTC-positive hepatocytes) was then calculated 
per adjusted area (total area minus empty area), and the values were averaged for each liver.
To determine the percentage of Cas9-positive hepatocytes, two sections from each liver were 
analyzed, one stained for Cas9 (via FLAG tag), the other section stained with hematoxylin to 
label all nuclei. Three images from every section were taken with a 10x objective, and the 
number of either Cas9-positive or hematoxylin-stained hepatocyte nuclei was determined 
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using ImageJ’s “Analyze Particles” tool that allows one to select and count stained 
hepatocyte nuclei. Hematoxylin-stained nuclei from other cell types could be excluded based 
on size and circularity parameters. The percentage of Cas9-positive nuclei was then 
calculated based on the total number of hepatocyte nuclei visible in the hematoxylin-stained 
sections.
Histopathology
Hematoxylin and eosin (H&E) staining was performed on sections from paraffin-embedded 
liver samples processed and stained according to standard protocols. Sections were analyzed 
for any abnormalities compared to livers from untreated animals.
OTC enzyme activity assay
OTC enzyme activity was assayed in liver lysates as described previously with 
modifications35. Whole-liver fragments were frozen in liquid nitrogen and stored at −80°C 
until OTC measurements were performed. A homogenate of 50 mg liver tissue per mL was 
prepared in 50 mM Tris acetate buffer, pH 7.5, with a Polytron homogenizer (Kinematica 
AG). A total of 250 μg of liver tissue was used per assay tube, and assays were performed in 
duplicate. The protein concentration was determined on the remaining liver homogenate 
using the Bio-Rad Protein assay kit (Bio-Rad) according to the manufacturer’s instructions.
Western blot analysis
Western blot analyses were performed on liver lysates as described previously36. OTC 
protein was detected by a custom rabbit polyclonal antibody (1:10,000 dilution)34. Mouse 
anti-FLAG M2 antibody (1:2000 dilution, Sigma, Cat# F1804) and mouse anti-actin 
antibody (1:1,000 dilution, Cell Signaling Technology, Cat# 8457L) were used to detect 
Cas9 and actin. Blots were imaged with ChemiDoc MP system and analyzed using 
ImageLab 4.1 software (Bio-Rad).
Gene expression analysis and RT-qPCR
RNA was isolated using Trizol (Life Technology) and reverse-transcribed using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). qPCR to measure murine 
OTC, SaCas9, and GAPDH were performed using gene-specific primers (Life 
Technologies). Data were normalized to GAPDH levels.
On-target and off-target mutagenesis analyses
HDR-mediated targeted modifications were confirmed by restriction-fragment length 
polymorphism (RFLP) analysis, as described previously31. The HDR-Fwd and HDR-Rev 
primers were designed to anneal outside of the region of homology between the donor 
template and targeted genomic region. The PCR products were purified and digested with 
AgeI restriction enzyme. To further analyze the OTC intron 4 on-target site, the genomic 
region was amplified by nested PCR. Briefly, the genomic DNA was first amplified by the 
HDR-Fwd and HDR-Rev primers (Supplementary Table 5) using Q5® High-Fidelity DNA 
Polymerase (New England Biolabs) and gel purified to remove the residual 
AAV8.sgRNA1.donor in the genomic DNA. Then nested PCR was performed by using the 
Yang et al. Page 9
Nat Biotechnol. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
purified 1st round PCR amplicon. Libraries were made from 250 ng of the 2nd PCR 
products using NEBNext® Ultra™ DNA Library Prep Kit for Illumina (NEB) and sequenced 
on Illumina MiSeq (2×250 base pair (bp) paired end or 2×300 bp paired end, Genewiz). 
Data were processed according to standard Illumina sequencing analysis procedures. 
Processed reads were mapped to the expected PCR amplicons as reference sequences using 
custom scripts. Reads that did not map to reference were discarded. Insertions and/or 
deletions were determined by comparison of reads against reference using custom scripts. 
The indel sequences as summarized for the OTC intron 4 on-target site are presented in 
Supplementary Table 2.
The most likely off-target sites were determined using the algorithm described in 
www.benchling.com, referred to as OT1 through OT16 (Supplementary Table 4). Primers 
spanning these sites (Supplementary Table 6) were used to amplify relevant sequences by 
nested PCR. Purified PCR fragments were then subjected to deep sequencing as described 
above.
Frequencies of on-target and off-target indels and on-target correction of the spfash mutation 
were determined as follows. MiSeq reads were analyzed using custom scripts to identify 
indels by matching reads against reference, with indels involving any portion of the 
sequence within 15 nt upstream or downstream of the predicted CRISPR-Cas9 cleavage site 
(3 nt downstream of the PAM, within the protospacer) considered to be possible off-target 
effects. Reads for which there was any 18-nt sequence with more than 2 mismatches with 
the corresponding 18-nt portion of the reference sequence, either upstream or downstream of 
a candidate indel, were discarded as errors. All candidate indels for the OT1 through OT16 
sites were manually curated for confirmation.
For the OTC intron 4 on-target site, a read was counted as having “Perfect HDR” if on the 
antisense strand there was a perfect match with a 51-nt sequence from the donor, starting 
with the donor-specific ‘CACCAA’ at the location of the PAM, through the donor-specific 
AgeI insert ‘ACCGGT’, and ending with the SNV ‘C’ at the spfash OTC mutation site. A 
read was counted as being a “Read with a ‘G’” if it either (1) met the criterion for “Perfect 
HDR” or (2) had the SNV ‘G’ on the sense strand in the expected spfash OTC mutation site 
54 nt upstream of the predicted CRISPR-Cas9 cleavage site (accounting for the size of the 
donor-specific AgeI insert ‘ACCGGT’), with up to two mismatches with the 18-nt intronic 
portion of the reference sequence adjacent to the spfash OTC mutation site. A read was 
counted as having “Partial HDR” if it did not meet the criteria for “Perfect HDR” and “Read 
with a ‘G’” and if there was a perfect match with an 18-nt sequence from the donor, starting 
with the donor-specific ‘CACCAA’ at the 3′ end of the target site and ending with the donor-
specific AgeI insert ‘ACCGGT’.
Statistical analyses
Test and control vectors were evaluated in at least 3 mice per group at each time point to 
ensure reproducibility. Sample sizes are noted in figure legends. All animals with successful 
temporal vein injection were included in the study analysis. Those animals with 
unsuccessful injection were excluded. Injection success was determined according to vector 
Yang et al. Page 10
Nat Biotechnol. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
genome copies in liver via qPCR, where animals with vector genome copies <10% of the 
mean value of the dosing group at the same time point were considered to be unsuccessful.
Statistical analyses were performed with GraphPad Prism 6.03 for Windows. The Dunnett’s 
multiple comparisons test was used to compare a number of variables with a single control. 
Due to the relatively small sample size, normality testing was not feasible. The Mantel-Cox 
test was used to test the survival distributions for differences. Group averages are presented 
as mean ± S.E.M.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. In vivo gene correction of the OTC locus in the spfash mouse liver by AAV.CRISPR-
SaCas9
(a) Schematic diagram of the mouse OTC locus showing the spfash mutation and three 
SaCas9 targets. spfash has a G-to-A mutation at the donor splice site at the end of exon 4 
indicated in red on the top strand. The three selected SaCas9-targeted genomic sites (20 bp 
each) are in blue and underlined with the PAM sequences marked in green. The black line 
above exon 4 indicates the 1.8 kb OTC donor template. (b) Dual AAV vector system for 
liver-directed and SaCas9-mediated gene correction. The AAV8.sgRNA1.donor vector 
contains a 1.8-kb murine OTC donor template sequence as shown in (a) with the 
corresponding PAM sequence mutated and an AgeI site inserted. (c) Flowchart showing the 
key steps of AAV8.CRISPR-SaCas9-mediated gene correction in the neonatal OTC spfash 
model.
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Figure 2. Efficient restoration of OTC expression in the liver of spfash mice treated at neonatal 
stage by AAV8.CRISPR-SaCas9-mediated gene correction
AAV8.SaCas9 (5×1010 GC/pup) and AAV8.sgRNA1.donor (5×1011 GC/pup) were 
administrated to postnatal day 2 (p2) spfash pups via the temporal vein. spfash mice were 
sacrificed at 3 (n=5) or 8 weeks (n=8) after treatment. Untargeted spfash mice received 
AAV8.SaCas9 (5×1010 GC/pup) and AAV8.control.donor (5×1011 GC/pup) at p2, and livers 
were harvested 8 weeks post treatment (n=6). Untreated WT (n=3) and spfash mice (n=3) 
were included as controls. (a) Immunofluorescence staining with antibodies against OTC on 
liver sections from spfash mice treated with the dual AAV vectors for CRISPR-SaCas9-
mediated gene correction. Stained areas typically represent clusters of corrected hepatocytes. 
Untreated controls show livers from wild type, spfash heterozygous, and spfash hemizygous 
mice. Scale bar, 100μm. (b) Quantification of gene correction based on the percentage of 
area on liver sections expressing OTC by immunostaining as presented in panel a. (c) 
Random distribution of clusters of corrected hepatocytes along the portal-central axis shown 
by double immunostaining against OTC (red) and glutamine synthetase (GS, green), which 
is a marker of central veins (p, portal vein; c, central vein). Scale bars, 300 μm (upper panel) 
and 100 μm (lower panel). (d) Groups of corrected hepatocytes expressing OTC (red) shown 
by immunofluorescence on sections co-stained with fluorescein-labeled tomato lectin 
(Lycopersicon esculentum lectin, LEL; green) which outlines individual hepatocytes. Scale 
bar, 50μm. (e) OTC enzyme activity in the liver lysate of spfash mice at 3 and 8 weeks 
following dual vector treatment. (f) Quantification of OTC mRNA levels in the liver by RT-
qPCR using primers spanning exons 4–5 to amplify wild-type OTC. Mean ± SEM are 
shown. * P < 0.05, ** P < 0.01, *** P < 0.001, Dunnett’s test.
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Figure 3. Time course of SaCas9 expression following neonatal vector administration and 
functional improvement following high-protein diet challenge
(a) Immunostaining with antibodies against FLAG on liver sections from an untreated 
mouse or treated spfash mice at 1, 3, or 8 weeks following neonatal injection of the dual 
AAV vectors for CRISPR-SaCas9-mediated gene correction. AAV8.SaCas9 (5×1010 GC/
pup) and AAV8.sgRNA1.donor (5×1011 GC/pup) were administrated to p2 spfash pups via 
the temporal vein. Nuclear staining of FLAG-tagged SaCas9 were abundant at 1 week (n=5) 
but dramatically reduced at 3 weeks (n=6) and became scarce at 8 weeks (n=7) after vector 
injection. Scale bar, 100 μm. (b) Quantification of SaCas9 mRNA levels in liver by RT-
qPCR. Mean ± SEM are shown. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, 
Dunnett’s test. (c) Quantification of SaCas9 vector genome in liver by qPCR. (d, e) Plasma 
ammonia levels and survival curves in control or dual AAV vector-treated spfash mice after a 
one-week course of high-protein diet. Seven weeks following neonatal treatment with the 
dual AAV vectors, mice were given high-protein diet for 7 days. (d) Plasma ammonia levels 
were measured 7 days after the high-protein diet. Plasma ammonia levels in WT mice 
(n=13) and AAV8.SaCas9 + AAV8.sgRNA1.donor-treated spfash mice (n=13) were 
significantly lower than untreated spfash mice (n=16) after a 7-day high-protein diet. Red 
squares indicate samples obtained from moribund untreated spfash mice 6 days after high-
protein diet; red triangle indicates sample obtained from a moribund spfash mouse treated 
with untargeted vector (AAV8.control.donor with no sgRNA1, n=10) 5 days after high-
protein diet. ** P< 0.01, **** P< 0.0001, Dunnett’s test. (e) Untreated spfash mice (n=20) or 
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spfash mice treated with untargeted vectors (AAV8.control.donor, n=13) started to die 3 days 
after high-protein diet. All WT (n=13) and AAV8.SaCas9 + AAV8.sgRNA1.donor-treated 
mice (n=13) survived. * P< 0.05, Mantel-Cox test.
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Figure 4. Gene targeting/correction in the liver of spfash mice treated as adults by 
AAV8.CRISPR-SaCas9 vectors
Adult spfash mice (8–10 weeks old) received an intravenous injection of AAV8.SaCas9 
(1×1011 GC) and AAV8.sgRNA1.donor (1×1012 GC), or higher dose of AAV8.SaCas9 
(1×1012 GC) and AAV8.sgRNA1.donor (5×1012 GC), or untargeted vectors at the equivalent 
doses. (a) Immunofluorescence staining with antibodies against OTC on liver sections 
collected at 3 (low-dose, n=3) or 2 weeks (high-dose, n=3) after injection. Stained cells 
typically showed as single corrected hepatocytes. Scale bar, 100μm. (b) Isolated corrected 
hepatocytes expressing OTC (red) shown by immunofluorescence on sections co-stained 
with fluorescein-labeled tomato lectin (LEL; green) which outlines individual hepatocytes. 
Scale bar, 50μm. (c) Survival curve of the low-dose cohorts: sgRNA1 (n=10) or untargeted 
vector at the same dose (n=5). (d) Survival curve of the high-dose cohorts: sgRNA1 (n=5) or 
untargeted vector at the same doses (n=5). The experiment was terminated at 14 days post 
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vector injection. (e) Change of urine orotic acid levels in adult spfash mice after treatment 
with high-dose gene targeting vectors (n=3 for untreated spfash and low-dose groups; n=2 for 
high-dose groups) (f) Elevation of plasma NH3 levels in adult spfash mice after treatment 
with high-dose gene targeting vectors (n=3 for each group). Mean ± SEM are shown. *** P 
< 0.001, **** P < 0.0001, Dunnett’s test.
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